Where are the biggest cardiovascular benefits for your patients with type 2 diabetes? Host Dr Silvio Inzucchi and cardiologist Dr Mikhail Kosiborod reveal winning strategies — for managing much more than just type 2 diabetes.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963270). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.

Resources

New ACC Guidance on CVD Risk Reduction in Diabetes https://www.medscape.com/viewarticle/935218

Type 2 Diabetes in Adults: Management https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#blood-glucose-management

Type 2 Diabetes and Causes of Sudden Cardiac Death: A Systematic Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525691/

Cardiometabolic Medicine – the US Perspective on a New Subspecialty https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410029/pdf/xce-9-070.pdf

Antidiabetics, Glucagon-like Peptide-1 Agonists https://reference.medscape.com/drugs/antidiabetics-glucagon-like-peptide-1-agonists

Antidiabetics, SGLT2 Inhibitors https://reference.medscape.com/drugs/antidiabetics-sglt2-inhibitors

Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/31189511/

Mechanistic Insights Regarding the Role of SGLT2 Inhibitors and GLP1 Agonist Drugs on Cardiovascular Disease in Diabetes https://pubmed.ncbi.nlm.nih.gov/31381891/

SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-analysis of Cardiovascular Outcome Trials https://pubmed.ncbi.nlm.nih.gov/30424892/

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial https://pubmed.ncbi.nlm.nih.gov/33736819/

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1812389

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis https://diabetesjournals.org/care/article/39/7/1108/37341/CV-Protection-in-the-EMPA-REG-OUTCOME-Trial-A

Worldwide Inertia to the Use of Cardiorenal Protective Glucose-Lowering Drugs (SGLT2i and GLP-1 RA) in High-Risk Patients with Type 2 Diabetes https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01154-w

Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/30291013/

High-Sensitivity C-Reactive Protein https://emedicine.medscape.com/article/2094831-overview#:~:text=hs%2DCRP%20is%20an%20important,predicts%20mortality%20and%20cardiac%20complications.

Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists: 5 Things to Know https://www.medscape.com/viewarticle/960356

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34215025/

Coronary Artery Calcification on CT Scanning https://emedicine.medscape.com/article/352189-overview